NCT04689204View on ClinicalTrials.gov

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

December 29, 2022

Study Completion Date

May 31, 2024

Conditions
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
Interventions
DRUG

CTA30X

CTA30X cell injection by intravenous infusion

Trial Locations (1)

310003

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

He Huang

OTHER

NCT04689204 - A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies | Biotech Hunter | Biotech Hunter